Actions and Detail Panel
King's Health Partners Diabetes, Endocrinology and Obesity Institute and Ne...
Fri 5 May 2017, 09:00 – 16:00 BST
King's Health Partners are delighted to announce the launch of a clinical and academic Diabetes, Endocrinology and Obesity Institute and Network. This will be developed over the next few years in collaboration with local and regional partners to optimise delivery of world-class clinical care, highly innovative and translational research and world-class postgraduate education programmes.
We are holding a free event on Friday 5 May that will showcase our current clinical and academic strengths in diabetes, endocrinology and obesity, and presents our vision for the Institute and our wider health Network.
A full programme will be circulated shortly; key confirmed speakers confirmed include:
Professor Stefan Bornstein
Since 2004, Professor Bornstein has been Director and Chair of the Department of Medicine at the University of Dresden, Germany. In 2012 he became Dean of International Affairs and Development at the University of Dresden. and in 2013 he was appointed Chair and Honorary Consultant, Endocrinology and Diabetes, King’s College London. In March 2015, in 2015 his appointment as Transcampus Dean (King's College London and the University of Dresden) was announced. Professor Borstein's main research interests focus on lipid-, steroid- and catecholamine metabolism, immune endocrine crosstalk, type 1 diabetes, islet transplantation and mechanisms of hypertension in the metabolic syndrome. He has (co)authored more than 500 Medline-cited scientific papers and contributed to numerous books.
Professor Stephanie Amiel
Professor Amiel is RD Lawrence Professor of Diabetic Medicine. She has an international reputation in the investigation and management of hypoglycaemia in Type 1 diabetes. Her work on the aetiopathogenesis of hypoglycaemia unawareness is currently focussed on pharmacological manipulation of cognitive function and counterregulation to hypoglycaemia in diabetes; investigation of new technologies in hypoglycaemia avoidance during insulin therapy and the use of neuroimaging to investigate abnormalities in cortical function and counterregulation to hypoglycaemia.Professor Amiel is chair of the National Dose Adjustment For Normal Eating (DAFNE) Executive Committee
Professor Khalida Ismail
Professor of Psychiatry and Medicine at the Institute of Psychiatry, King's College London and Consultant Liaison Psychiatrist at King's College Hospital NHS Foundation Trust.
She leads the Diabetes and Mental Health Research Group and the Diabetes and Psychiatry clinical service at King's Health Partners. Her research has been translated into innovative clinical services such as the 3 Dimensions of Care for Diabetes service (3DFD) which won 3 Quality in Care Awards 2011. She has developed training modules to improve skills in psychological care for health professionals working with people with diabetes. Her research interests include, understanding the epidemiology and underlying mechanisms of the depression-diabetes link and related disorders and developing and evaluating complex interventions to improve diabetes control and depression.
Dr David Hopkins
Dr Hopkins is a Consultant Physician and Clinical Director for Ambulatory Medicine at King's College Hospital. Dr Hopkins leads one of the largest specialist diabetes teams in the UK and has broad clinical interests including insulin pump management, diabetic nephropathy, neuropathy, transplantation and cystic fibrosis. He is leading the KHP programme to develop a diabetes data warehouse to support clinical practice and research. Other academic interests include hypoglycaemia, outcomes of structured patient education in type 1 diabetes and novel treatments for type 2 diabetes and obesity.
Professor Mark Peakman
Mark Peakman is Professor of Clinical Immunology, Consultant Immunologist and Head of the KCL Division of Diabetes and Nutritional Sciences. His major research interest is Type 1 diabetes, and he has spent many years studying the immune basis for the disease. This has led to the development of pioneering therapeutic approaches currently the subject of Phase I/II studies in the UK and US. Mark is on the Executive of Type 1 Diabetes TrialNet, an international diabetes trial consortium where he leads on the mechanistic portfolio.